Header Logo

Connection

Rajagopal Ramesh to Female

This is a "connection" page, showing publications Rajagopal Ramesh has written about Female.
Connection Strength

0.452
  1. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J Ovarian Res. 2024 May 25; 17(1):113.
    View in: PubMed
    Score: 0.072
  2. A Non-invasive Liquid Biopsy Screening of Urine-Derived Exosomes for miRNAs as Biomarkers in Endometrial Cancer Patients. AAPS J. 2018 07 09; 20(5):82.
    View in: PubMed
    Score: 0.048
  3. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.044
  4. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine. 2014; 9:3825-39.
    View in: PubMed
    Score: 0.036
  5. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm. 2014 Aug 04; 11(8):2720-33.
    View in: PubMed
    Score: 0.036
  6. Nanoparticle-mediated gene delivery to the lung. Methods Mol Biol. 2008; 433:301-31.
    View in: PubMed
    Score: 0.023
  7. Vitamin E succinate in combination with mda-7 results in enhanced human ovarian tumor cell killing through modulation of extrinsic and intrinsic apoptotic pathways. Cancer Lett. 2007 Sep 08; 254(2):217-26.
    View in: PubMed
    Score: 0.022
  8. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer. 2007 Feb 02; 6:11.
    View in: PubMed
    Score: 0.022
  9. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007 Feb; 15(2):287-94.
    View in: PubMed
    Score: 0.022
  10. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res. 2005 Apr 15; 65(8):3017-24.
    View in: PubMed
    Score: 0.019
  11. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat. 2004 Dec; 3(6):647-57.
    View in: PubMed
    Score: 0.019
  12. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol. 2004 Dec; 23(12):850-7.
    View in: PubMed
    Score: 0.019
  13. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003 Aug 15; 63(16):5105-13.
    View in: PubMed
    Score: 0.017
  14. RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer. Adv Drug Deliv Rev. 2022 Dec; 191:114569.
    View in: PubMed
    Score: 0.016
  15. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Apr; 37(4):2382-2390.
    View in: PubMed
    Score: 0.011
  16. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016 10 04; 7(40):64820-64835.
    View in: PubMed
    Score: 0.011
  17. Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 2013 Sep 20; 24(37):375104.
    View in: PubMed
    Score: 0.008
  18. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15.
    View in: PubMed
    Score: 0.005
  19. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002 Sep; 8(9):2963-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.